Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01390792

Enrollment

622

Registered

2011-07-11

Start date

2007-01-31

Completion date

2009-05-31

Last updated

2017-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza, Human

Brief summary

The purpose of this post-marketing surveillance study is to collect information on efficacy and safety for prophylactic administration of zanamivir in clinical practice in family or persons living with patients with influenza virus infection.

Interventions

DRUGZanamivir hydrate

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Inclusion criteria

* Subjects who meet the study population criteria

Exclusion criteria

* Subjects with a history of hypersensitivity to the ingredients of zanamivir

Design outcomes

Primary

Measure	Time frame
The number of incidence of adverse events in subjects treated with zanamivir	11 days
Occurrence of influenza virus infection	11 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026